Canaccord Genuity Group Lowers ANI Pharmaceuticals (NASDAQ:ANIP) Price Target to $90.00

ANI Pharmaceuticals (NASDAQ:ANIP) had its price target dropped by investment analysts at Canaccord Genuity Group from $91.00 to $90.00 in a report released on Monday,Benzinga reports. The firm currently has a “hold” rating on the specialty pharmaceutical company’s stock. Canaccord Genuity Group’s price objective indicates a potential upside of 15.02% from the company’s previous close.

Other analysts have also recently issued research reports about the company. Wall Street Zen cut ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Weiss Ratings raised ANI Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, June 23rd. Guggenheim restated a “buy” rating and set a $124.00 price objective on shares of ANI Pharmaceuticals in a research note on Friday, July 10th. Finally, Zacks Research lowered ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 14th. Five analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, ANI Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $106.67.

ANI Pharmaceuticals Price Performance

Shares of ANIP opened at $78.25 on Monday. The company has a debt-to-equity ratio of 0.99, a quick ratio of 2.41 and a current ratio of 2.91. The company has a 50 day moving average price of $81.02 and a 200-day moving average price of $79.33. ANI Pharmaceuticals has a fifty-two week low of $70.15 and a fifty-two week high of $99.50. The stock has a market capitalization of $1.78 billion, a PE ratio of 16.86 and a beta of 0.44.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings data on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.04 by $0.17. The company had revenue of $266.04 million for the quarter, compared to analyst estimates of $260.13 million. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. ANI Pharmaceuticals’s revenue was up 25.8% compared to the same quarter last year. During the same period last year, the company posted $1.80 earnings per share. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Equities analysts predict that ANI Pharmaceuticals will post 8.03 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, VP Meredith Cook sold 500 shares of the company’s stock in a transaction dated Monday, July 13th. The shares were sold at an average price of $81.84, for a total transaction of $40,920.00. Following the transaction, the vice president owned 77,390 shares in the company, valued at $6,333,597.60. This represents a 0.64% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Thomas Haughey sold 2,000 shares of the stock in a transaction that occurred on Monday, June 8th. The shares were sold at an average price of $80.88, for a total transaction of $161,760.00. Following the completion of the transaction, the director directly owned 38,878 shares of the company’s stock, valued at $3,144,452.64. The trade was a 4.89% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 29,056 shares of company stock valued at $2,367,302 in the last 90 days. 8.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. KBC Group NV acquired a new position in shares of ANI Pharmaceuticals in the 1st quarter valued at $28,000. Advisors Asset Management Inc. acquired a new position in shares of ANI Pharmaceuticals in the first quarter valued at about $28,000. Hantz Financial Services Inc. raised its stake in shares of ANI Pharmaceuticals by 70.3% in the fourth quarter. Hantz Financial Services Inc. now owns 603 shares of the specialty pharmaceutical company’s stock worth $48,000 after purchasing an additional 249 shares during the last quarter. Kemnay Advisory Services Inc. acquired a new stake in shares of ANI Pharmaceuticals during the fourth quarter worth about $48,000. Finally, State of Wyoming purchased a new stake in ANI Pharmaceuticals in the second quarter valued at approximately $50,000. Institutional investors and hedge funds own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.